What is Protagenic Therapeutics 5-Year EBITDA Growth Rate?
Protagenic Therapeutics's EBITDA per Share for the
three
months ended in Dec. 2023 was $-0.37.
During the past 3 years, the average EBITDA Per Share Growth Rate was -7.90% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was -3.70% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 44.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Protagenic Therapeutics was 83.80% per year. The lowest was -7.90% per year. And the median was 13.85% per year.
Competitive Comparison of Protagenic Therapeutics's 5-Year EBITDA Growth Rate
For the Biotechnology subindustry, Protagenic Therapeutics's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Protagenic Therapeutics's 5-Year EBITDA Growth Rate Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Protagenic Therapeutics's 5-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Protagenic Therapeutics's 5-Year EBITDA Growth Rate falls into.
This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.
Protagenic Therapeutics 5-Year EBITDA Growth Rate Related Terms
Thank you for viewing the detailed overview of Protagenic Therapeutics's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.
Protagenic Therapeutics (Protagenic Therapeutics) Business Description
Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression and neurodegenerative disorders by using peptide-based and brain active therapeutics. The company's lead compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PTIX has been successfully added to your